GO:0048039 ubiquinone binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048039 (ubiquinone binding) is a molecular function describing the selective, non-covalent interaction of a protein with ubiquinone (coenzyme Q), a lipid-soluble benzoquinone with an isoprenoid tail.
• Ubiquinone binding sites are best characterized in respiratory complexes I and II, where crystallography and cryo-EM have resolved the quinone-binding cavity and its conformational transitions.
• Ubiquinone-binding proteins can be identified computationally from sequence and structure, enabling systematic annotation of Q-binding candidates across genomes.
• Kinetic and structural data show that ubiquinone binding is coupled to reduction and to large-scale conformational changes in respiratory complex I.
• Ubiquinone-binding proteins are also exploited analytically, for example as coenzyme Q-binding reagents in assay development.
• Dysregulation of ubiquinone biosynthesis and binding contributes to hypoxia-related cardiac injury and other mitochondrial phenotypes.
Description
Ubiquinone binding (GO:0048039) is the molecular function of selectively and reversibly associating with ubiquinone, a quinone derivative bearing a tail of isoprene units. Ubiquinone, also called coenzyme Q, is the central lipid-soluble electron carrier of respiratory and photosynthetic electron transport chains, and its binding to protein partners is the physical event that positions the quinone for redox chemistry. Because the quinone headgroup must reach buried catalytic sites while its isoprenoid tail remains in the membrane, ubiquinone-binding proteins have evolved specialized cavities and gating mechanisms that are now resolved at atomic resolution. For researchers, GO:0048039 is a functional annotation that links sequence and structure to a defined biochemical activity. Proteins annotated with this term include the quinone-binding subunits of respiratory complex I and complex II, as well as soluble and membrane-associated proteins that sequester or transport ubiquinone. The term is therefore useful in genome annotation, in structural biology pipelines, and in the interpretation of mitochondrial disease variants that alter quinone chemistry. Mechanistically, ubiquinone binding is not a passive event. Structural and kinetic studies demonstrate that occupancy of the Q-site is coupled to protein conformational transitions and to electron transfer, making the binding step a regulatory node in respiration. This article summarizes the definition, structural basis, key proteins, disease links, and experimental methods relevant to GO:0048039.
ubiquinone binding At A Glance
| GO ID | GO:0048039 |
|---|---|
| GO term | ubiquinone binding |
| Ontology | molecular_function |
| Synonym | coenzyme Q6 binding; coenzyme Q binding |
| Definition | Binding to ubiquinone, a quinone derivative with a tail of isoprene units. |
| Major function | Selective, non-covalent recognition of ubiquinone (coenzyme Q) by a protein, positioning the quinone for redox chemistry or transport. |
| Representative proteins | Quinone-binding subunits of respiratory complex I and complex II, and other ubiquinone-binding proteins. |
| Structural basis | Buried or membrane-accessible Q-binding cavities resolved by crystallography and cryo-EM. |
| Disease relevance | Mitochondrial dysfunction, hypoxia-related cardiac injury, and disorders of coenzyme Q metabolism. |
What Is GO:0048039?
In the Gene Ontology, GO:0048039 (ubiquinone binding) is a molecular function defined as binding to ubiquinone, a quinone derivative with a tail of isoprene units. It describes the selective, non-covalent interaction between a protein and ubiquinone (coenzyme Q), including the recognition of the quinone ring and the accommodation of the isoprenoid tail. The function is distinct from ubiquinone biosynthesis or ubiquinone-mediated electron transfer per se, although binding is a prerequisite for both.
Why Is ubiquinone binding Important in Cell Biology?
Ubiquinone binding is important because it is the molecular recognition step that places coenzyme Q at the catalytic site of respiratory complexes and other quinone-dependent proteins, thereby enabling electron transfer, proton translocation, and cellular redox homeostasis. Because the quinone-binding site is a druggable cavity, structural knowledge of ubiquinone binding directly informs inhibitor design against respiratory complex II and related enzymes. The term also provides a functional annotation that helps researchers interpret genomic and structural data, prioritize candidate genes, and connect mitochondrial variants to biochemical phenotypes.
• Defines the selective protein-quinone interaction required for respiratory electron transport.
• Provides a druggable cavity exploited by complex II inhibitors and other respiratory-chain compounds.
• Enables computational identification and annotation of ubiquinone-binding proteins across genomes.
• Explains how Q-site occupancy triggers conformational transitions in respiratory complex I.
• Supports structure-based interpretation of yeast and mammalian NADH dehydrogenase quinone sites.
• Links binding kinetics to the reduction chemistry of ubiquinone.
• Underpins analytical applications such as coenzyme Q determination using ubiquinone-binding proteins.
• Connects ubiquinone biosynthesis and binding to hypoxia-related cardiac injury.
• Helps interpret mitochondrial disease variants that perturb quinone chemistry.
• Serves as a functional annotation node in genome-scale and structural bioinformatics pipelines.
Molecular Mechanism of ubiquinone binding
Recognition of the quinone headgroup
In simple terms: The protein has a pocket shaped to hold the quinone ring.
Ubiquinone binding begins with recognition of the benzoquinone headgroup by a protein cavity that complements the ring's size, polarity, and redox state. Crystallographic investigation of the respiratory complex II ubiquinone-binding site has defined the residues and water molecules that contact the quinone ring and its inhibitors, establishing a structural template for headgroup recognition. In yeast NADH dehydrogenase, structures with competitive and mixed-type inhibitors revealed how the quinone headgroup is positioned within the binding site.
Accommodation of the isoprenoid tail
In simple terms: The long greasy tail of ubiquinone sits in a channel that anchors it in the membrane.
Because ubiquinone carries a tail of isoprene units, the binding site must provide a hydrophobic channel or membrane-accessible groove that accommodates the tail while keeping the headgroup at the catalytic position. Cryo-EM structures of mitochondrial complex I have defined ubiquinone-10 binding and the conformational transitions that accompany Q-site occupancy, showing how the long tail is housed within the membrane domain. This tail accommodation is a defining feature that distinguishes ubiquinone binding from binding of short-chain quinones.
Coupling of binding to conformational change
In simple terms: When the quinone docks, the protein changes shape to do its job.
Ubiquinone binding is coupled to protein conformational transitions rather than being a static event. Cryo-EM structures of complex I show that Q-site occupancy is accompanied by defined conformational changes in the enzyme. Correlating kinetic and structural data on ubiquinone binding and reduction by respiratory complex I demonstrated that the binding step is mechanistically linked to the subsequent reduction chemistry. These observations place ubiquinone binding at the interface between recognition and catalysis.
Binding energetics and inhibitor competition
In simple terms: Other molecules can compete with ubiquinone for the same pocket.
The ubiquinone-binding site is a competitive cavity that can be occupied by inhibitors, which is why structural studies of complex II with inhibitors have been used to map the site. Yeast NADH dehydrogenase structures bound to competitive- and mixed-type inhibitors similarly revealed the quinone-binding site and its inhibitor interactions. These data show that ubiquinone binding is governed by competition and affinity, and that the site can be targeted pharmacologically.
Computational and analytical detection of ubiquinone binding
In simple terms: Software and assays can flag or measure ubiquinone binding.
Ubiquinone-binding proteins can be identified and analyzed computationally from sequence and structural features, supporting annotation of the function at genome scale. Experimentally, ubiquinone-binding proteins have been used as reagents for the determination of coenzyme Q, illustrating that the binding function can be harnessed analytically. Together, computational and analytical approaches complement structural and kinetic studies of GO:0048039.
Key Genes Involved in GO:0048039 ubiquinone binding
The following genes and proteins are representative of ubiquinone binding (GO:0048039) and its structural, catalytic, and analytical contexts.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SDHA | Flavoprotein subunit of respiratory complex II that contributes to the ubiquinone-binding site | Crystallographic mapping of the complex II ubiquinone-binding site and inhibitor interactions |
| SDHB | Iron-sulfur subunit of respiratory complex II adjacent to the quinone site | Structural and mechanistic studies of quinone reduction |
| SDHC | Membrane-anchored subunit of complex II forming part of the Q-binding cavity | Defines membrane-facing quinone access and inhibitor binding |
| SDHD | Membrane-anchored subunit of complex II contributing to the Q-site | Structural investigation of the ubiquinone-binding site |
| NDI1 | Yeast NADH dehydrogenase with a defined ubiquinone-binding site | Structures with competitive and mixed-type inhibitors reveal the Q-site |
| NDUFV1 | Complex I subunit in the catalytic arm near the quinone site | Cryo-EM analysis of ubiquinone-10 binding and conformational transitions |
| NDUFS2 | Complex I subunit contributing to the quinone-binding region | Kinetic and structural correlation of ubiquinone binding and reduction |
| NDUFS7 | Complex I subunit in the quinone-binding region | Structural and kinetic studies of Q-site chemistry |
| NDUFS3 | Complex I subunit associated with the quinone-binding cavity | Cryo-EM definition of Q-site occupancy |
| NDUFB8 | Accessory complex I subunit near the membrane arm | Structural context for ubiquinone-10 binding |
| COQ2 | Enzyme in ubiquinone biosynthesis | Links ubiquinone availability to binding-dependent processes |
| COQ3 | Enzyme in ubiquinone biosynthesis | Biosynthesis context relevant to ubiquinone binding studies |
| COQ5 | Enzyme in ubiquinone biosynthesis | Supports interpretation of ubiquinone-dependent phenotypes |
| COQ7 | Enzyme in ubiquinone biosynthesis | Connects biosynthesis to quinone-binding function |
| CIRBP | Cold-inducible RNA-binding protein linked to ubiquinone biosynthesis regulation | Hypoxia-induced hypermethylation attenuates cardioprotection via ubiquinone biosynthesis down-regulation |
| Ubiquinone-binding protein (generic) | Protein used as a reagent for coenzyme Q determination | Analytical application of ubiquinone binding |
How Is ubiquinone binding Regulated?
Ubiquinone binding is regulated at multiple levels. At the protein level, the availability and occupancy of the Q-site are influenced by conformational transitions of the enzyme, as shown for mitochondrial complex I where Q-site occupancy accompanies defined structural changes. At the level of substrate supply, ubiquinone biosynthesis determines the pool of quinone available for binding, and chronic hypoxia-induced Cirbp hypermethylation attenuates hypothermic cardioprotection via down-regulation of ubiquinone biosynthesis. Competitive and mixed-type inhibitors can occupy the site and modulate binding, as demonstrated for yeast NADH dehydrogenase. Together, these mechanisms indicate that ubiquinone binding is controlled by both protein conformation and quinone availability.
ubiquinone binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SDHA/SDHB/SDHC/SDHD | Respiratory complex II dysfunction and quinone-site inhibition | Knockout or point-mutation cell models of complex II subunits with Q-site assays |
| NDUFV1/NDUFS2/NDUFS7 | Complex I dysfunction linked to quinone binding and reduction | Knock-in or point-mutation models combined with cryo-EM and kinetics |
| NDI1 | Yeast model of NADH dehydrogenase quinone-site inhibition | Yeast knockout and inhibitor-binding structural studies |
| COQ2/COQ3/COQ5/COQ7 | Ubiquinone biosynthesis deficiency affecting quinone availability | Knockout cell models with ubiquinone supplementation |
| CIRBP | Hypoxia-induced cardiac injury via ubiquinone biosynthesis down-regulation | Hypoxia-exposed cardiomyocyte models with Cirbp perturbation |
Mitochondrial dysfunction and respiratory chain disorders
Because ubiquinone binding is required for electron transfer in respiratory complexes I and II, perturbations of the Q-site impair mitochondrial respiration. Structural and kinetic studies of complex I show that altered quinone binding and reduction are directly linked to enzyme function, providing a mechanistic basis for interpreting respiratory-chain phenotypes. Crystallographic mapping of the complex II ubiquinone-binding site further supports the view that this cavity is a focal point for dysfunction and for inhibitor action.
Hypoxia-related cardiac injury
Chronic hypoxia-induced Cirbp hypermethylation attenuates hypothermic cardioprotection via down-regulation of ubiquinone biosynthesis, linking the ubiquinone pathway to cardiac stress responses. Since ubiquinone binding depends on the availability of ubiquinone, reduced biosynthesis under hypoxia can indirectly compromise quinone-dependent functions. This provides a disease context in which ubiquinone binding and biosynthesis intersect.
Pharmacological targeting of quinone sites
The ubiquinone-binding site of respiratory complex II has been structurally investigated with inhibitors, establishing it as a targetable cavity. Yeast NADH dehydrogenase structures bound to competitive- and mixed-type inhibitors similarly demonstrate that quinone binding can be modulated pharmacologically. These findings support drug-discovery efforts aimed at quinone-binding sites in mitochondrial enzymes.
From ubiquinone binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene abolish ubiquinone binding? | CRISPR knockout cell line with quinone-binding assay |
| Does a specific residue mediate quinone headgroup recognition? | Point-mutation knock-in of the Q-site residue with structural validation |
| Does a disease variant alter Q-site occupancy? | Knock-in of the patient variant followed by cryo-EM or binding assays |
| Where does the protein bind ubiquinone in the cell? | Tagged knock-in with imaging and subcellular fractionation |
| Does overexpression of a ubiquinone-binding protein change respiration? | Overexpression cell model with respirometry and quinone measurements |
| Can inhibitors compete with ubiquinone binding? | Wild-type and point-mutant models treated with competitive inhibitors |
How to Study the ubiquinone binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| X-ray crystallography | Atomic structure of the ubiquinone-binding site | Mapping complex II Q-site and inhibitor contacts |
| Cryo-EM | Structure and conformational transitions upon Q-site occupancy | Defining ubiquinone-10 binding to complex I |
| Kinetic assays | Rates of ubiquinone binding and reduction | Correlating binding with catalysis in complex I |
| Inhibitor-binding structural studies | Competitive and mixed-type inhibitor interactions at the Q-site | Characterizing yeast NADH dehydrogenase quinone site |
| Computational sequence/structure analysis | Predicted ubiquinone-binding proteins | Genome-scale annotation of GO:0048039 |
| Coenzyme Q determination assays | Quinone levels using ubiquinone-binding proteins | Analytical quantification of coenzyme Q |
| Hypoxia and methylation models | Ubiquinone biosynthesis and downstream binding capacity | Studying hypoxia-related cardiac injury |
Structural methods: crystallography and cryo-EM
X-ray crystallography has been used to investigate the ubiquinone-binding site of respiratory complex II and its inhibitors, defining the residues and waters that contact the quinone ring. Cryo-EM structures have defined ubiquinone-10 binding to mitochondrial complex I and the conformational transitions accompanying Q-site occupancy. Yeast NADH dehydrogenase structures with competitive and mixed-type inhibitors further illustrate how structural methods reveal quinone-site architecture.
Kinetic and biochemical assays
Correlating kinetic and structural data on ubiquinone binding and reduction by respiratory complex I provides a framework for measuring the binding step and its coupling to catalysis. Ubiquinone-binding proteins have also been used as reagents for the determination of coenzyme Q, demonstrating a practical biochemical assay format. These approaches allow researchers to quantify binding and reduction in parallel.
Computational identification and annotation
Computational identification and analysis of ubiquinone-binding proteins enables systematic detection of the function from sequence and structure, supporting genome-scale annotation of GO:0048039. Such pipelines complement experimental structural and kinetic work by prioritizing candidate proteins for validation.
Disease-relevant functional models
Hypoxia-induced Cirbp hypermethylation attenuates hypothermic cardioprotection via down-regulation of ubiquinone biosynthesis, providing a disease-relevant model in which ubiquinone availability and binding can be studied. Combining such models with structural and kinetic readouts helps connect ubiquinone binding to physiological outcomes.
How CRISPR Can Be Used to Study GO:0048039 ubiquinone binding
Knockout
CRISPR knockout of genes encoding ubiquinone-binding proteins or ubiquinone biosynthesis enzymes allows researchers to test whether the candidate is required for quinone-dependent function. Loss-of-function models can be combined with structural and kinetic readouts to determine the contribution of a specific Q-site protein. Computational annotation of ubiquinone-binding proteins helps prioritize which knockouts to generate.
Point Mutation
Point mutations in residues that contact the ubiquinone headgroup or tail can be introduced to test their role in binding, guided by crystallographic and cryo-EM maps of the Q-site. Such models are useful for dissecting headgroup recognition versus tail accommodation. Yeast NADH dehydrogenase inhibitor-bound structures provide a template for selecting residues to mutate.
Knock-in
Knock-in of disease-associated or inhibitor-resistance variants into the endogenous locus enables study of ubiquinone binding in a physiological context. These models are particularly valuable when the variant is expected to alter Q-site occupancy or the coupling between binding and conformational change. Structural validation can then be performed by cryo-EM or crystallography.
Overexpression
Overexpression of ubiquinone-binding proteins can be used to test whether increased protein levels alter quinone binding capacity, respiration, or inhibitor sensitivity. Such models are also useful for producing protein for structural and analytical studies, including coenzyme Q determination assays. Combining overexpression with kinetic measurements helps link binding stoichiometry to function.
How EDITGENE Supports ubiquinone binding Research
Researchers studying ubiquinone binding-related genes often need to determine whether a candidate gene is causally involved in quinone recognition, respiratory function, or disease phenotypes. Establishing causality typically requires controlled genetic models in which the candidate locus is deleted, mutated, tagged, or overexpressed, followed by structural, kinetic, or biochemical readouts. EDITGENE provides the CRISPR and bioinformatics infrastructure to build such models and to interpret the resulting data in the context of GO:0048039.
Contact EDITGENE today to design your custom CRISPR model for ubiquinone binding research.
Frequently Asked Questions About ubiquinone binding
What is ubiquinone binding (GO:0048039)?
Ubiquinone binding is a Gene Ontology molecular function defined as binding to ubiquinone, a quinone derivative with a tail of isoprene units.
What genes are involved in ubiquinone binding?
Representative genes include respiratory complex II subunits (SDHA, SDHB, SDHC, SDHD), complex I subunits (NDUFV1, NDUFS2, NDUFS7, NDUFS3, NDUFB8), yeast NDI1, and ubiquinone biosynthesis genes such as COQ2, COQ3, COQ5, and COQ7.
Which proteins bind ubiquinone?
Ubiquinone-binding proteins include the quinone-binding subunits of respiratory complexes I and II and other proteins identified computationally as ubiquinone binders.
How is the ubiquinone-binding site structured?
The site contains a cavity that recognizes the quinone headgroup and a hydrophobic channel that accommodates the isoprenoid tail, as resolved by crystallography and cryo-EM.
Why is ubiquinone binding important for respiration?
Binding positions ubiquinone for reduction and is coupled to conformational transitions in respiratory complex I, making it essential for electron transfer.
Can ubiquinone binding be inhibited?
Yes, competitive and mixed-type inhibitors occupy the quinone-binding site, as shown for respiratory complex II and yeast NADH dehydrogenase.
How can I study ubiquinone binding in the lab?
Common approaches include X-ray crystallography, cryo-EM, kinetic assays, computational identification, and coenzyme Q determination assays using ubiquinone-binding proteins.
Is ubiquinone binding linked to disease?
Yes, perturbations of ubiquinone binding and biosynthesis are linked to mitochondrial dysfunction and to hypoxia-related cardiac injury.
What is the difference between ubiquinone binding and ubiquinone biosynthesis?
Ubiquinone binding (GO:0048039) is the molecular function of associating with ubiquinone, whereas biosynthesis refers to the enzymatic production of ubiquinone; the two are functionally connected because binding depends on quinone availability.
How do I model ubiquinone binding with CRISPR?
CRISPR knockout, point mutation, knock-in, and overexpression models can be combined with structural, kinetic, and biochemical readouts to test the role of specific Q-site residues and proteins.
Conclusion
GO:0048039 (ubiquinone binding) captures the selective molecular recognition of coenzyme Q by proteins, a function central to respiratory electron transport and to quinone-dependent biochemistry. Structural, kinetic, and computational studies have defined the Q-binding cavity, its conformational coupling, and its druggability, while disease models link ubiquinone availability and binding to mitochondrial and cardiac phenotypes. Researchers can now combine CRISPR genetic models with structural and biochemical methods to dissect ubiquinone binding with high precision.
References
- 1. Yu CA et al.. 1981. Ubiquinone-binding proteins.. Biochim Biophys Acta 639(2):99-128 PMID: 6272848
- 2. Huang LS et al.. 2021. Crystallographic investigation of the ubiquinone binding site of respiratory Complex II and its inhibitors.. Biochim Biophys Acta Proteins Proteom 1869(9):140679 PMID: 34089891
- 3. Lu C et al.. 2020. Computational Identification and Analysis of Ubiquinone-Binding Proteins.. Cells 9(2) PMID: 32102444
- 4. Chung I et al.. 2022. Cryo-EM structures define ubiquinone-10 binding to mitochondrial complex I and conformational transitions accompanying Q-site occupancy.. Nat Commun 13(1):2758 PMID: 35589726
- 5. Yamashita T et al.. 2018. Ubiquinone binding site of yeast NADH dehydrogenase revealed by structures binding novel competitive- and mixed-type inhibitors.. Sci Rep 8(1):2427 PMID: 29402945
- 6. Fedor JG et al.. 2017. Correlating kinetic and structural data on ubiquinone binding and reduction by respiratory complex I.. Proc Natl Acad Sci U S A 114(48):12737-12742 PMID: 29133414
- 7. Hagerman RA et al.. 2003. Ubiquinone binding protein used for determination of coenzyme Q.. Anal Biochem 320(1):125-8 PMID: 12895475
- 8. Liu Y et al.. 2019. Chronic hypoxia-induced Cirbp hypermethylation attenuates hypothermic cardioprotection via down-regulation of ubiquinone biosynthesis.. Sci Transl Med 11(489) PMID: 31019028
